Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [HEALTH]
2 clusters · 6 sources · 3 days · First seen · Last updated
CBL-514 clinical trial results for obesity treatment
Overview
Clinical trials for CBL-514, an injectable drug developed by Caliway Biopharmaceuticals, have demonstrated potential in treating obesity by inducing apoptosis, or programmed cell death, in fat cells. Unlike traditional treatments that shrink fat cells, this pharmacological approach aims to destroy them to prevent weight regain.
Phase II trial data from studies CBL-0204 and CBL-0205, presented at the European Association for the Study of Diabetes annual meeting, utilized MRI to track tissue changes. In a subgroup of 41 participants, those receiving the drug showed a significant reduction in visceral fat. Specifically, the CBL-514 group experienced a 63 ml reduction in visceral fat over 8 to 12 weeks, while the placebo group saw an increase of 78 ml, creating a total difference of 141 ml (22.21%) between the groups.
Medical experts noted that while subcutaneous fat loss offers cosmetic benefits, the primary health advantages involve the reduction of visceral fat, which can improve blood pressure and cholesterol levels.
Entities
CBL-514 · University of Alabama at Birmingham · Milan · European Association for the Study of Diabetes · Caliway Biopharmaceuticals
Timeline
-
[HEALTH] 2 sourcesCaliway Biopharmaceuticals reports fat reduction with CBL-514
Caliway Biopharmaceuticals' drug candidate CBL-514 demonstrated a 141 ml difference in visceral fat reduction compared to a placebo in Phase II trials, using apoptosis to target fat cells.
-
[HEALTH] 5 sourcesCBL-514 injection shows promise in destroying visceral fat cells
The injectable drug CBL-514 has shown promise in clinical trials by using apoptosis to destroy visceral fat cells, potentially offering a more permanent solution to obesity than current treatments.
Sources
ad-hoc-news.de · fehmarn24.de · hna.de · it-boltwise.de · op-online.de · sciencealert.com